| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/13543784.16.12.1933 |
| P8608 | Fatcat ID | release_jb2i7hphtrhbbeqq2zt6hf7tjy |
| P698 | PubMed publication ID | 18042002 |
| P50 | author | Robert J Ferrante | Q84362598 |
| P2093 | author name string | Edward C Stack | |
| P2860 | cites work | Creatine and cyclocreatine attenuate MPTP neurotoxicity | Q48223541 |
| Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease | Q48404266 | ||
| Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. | Q48537185 | ||
| The role of creatine kinase in inhibition of mitochondrial permeability transition | Q48621172 | ||
| Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats | Q48627086 | ||
| Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration | Q48670901 | ||
| Binding of antitumor antibiotic daunomycin to histones in chromatin and in solution. | Q53876425 | ||
| Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. | Q55032889 | ||
| Opening doors into the proteasome. | Q55034355 | ||
| Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice | Q56772848 | ||
| Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease | Q57628958 | ||
| Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons | Q24317574 | ||
| Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults | Q24558984 | ||
| MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms | Q24680714 | ||
| Argonaute2 is the catalytic engine of mammalian RNAi | Q27860545 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| The language of covalent histone modifications | Q27860931 | ||
| TOR, a central controller of cell growth | Q27933354 | ||
| Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice | Q28169162 | ||
| Mitochondria as a target for neurotoxins and neuroprotective agents | Q28186231 | ||
| Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease | Q28261987 | ||
| Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease | Q28262372 | ||
| The roles of intracellular protein-degradation pathways in neurodegeneration | Q28269322 | ||
| Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways | Q28277799 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| The biochemistry of apoptosis | Q29547741 | ||
| Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila | Q29616737 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy | Q29622819 | ||
| Therapeutic potential of RNA interference for neurological disorders | Q30047496 | ||
| ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease | Q30478632 | ||
| Pharmacological management of Huntington's disease: an evidence-based review | Q33250216 | ||
| Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease | Q33292417 | ||
| Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia | Q33612679 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease | Q33703899 | ||
| Bioenergetics in Huntington's disease | Q33836239 | ||
| Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. | Q33911613 | ||
| A randomized trial of amantadine in Huntington disease | Q45289614 | ||
| Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization | Q45291026 | ||
| Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory | Q45292146 | ||
| Assessment of coenzyme Q10 tolerability in Huntington's disease | Q45292398 | ||
| Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. | Q45293805 | ||
| Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. | Q45294902 | ||
| Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum | Q45295251 | ||
| Safety of intrastriatal neurotransplantation for Huntington's disease patients | Q45295583 | ||
| High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. | Q45296832 | ||
| Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts | Q45296864 | ||
| Selective sparing of a class of striatal neurons in Huntington's disease | Q45297134 | ||
| Biochemical abnormalities and excitotoxicity in Huntington's disease brain. | Q45297145 | ||
| Riluzole therapy in Huntington's disease (HD). | Q45297539 | ||
| Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial | Q45297817 | ||
| Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease | Q45298464 | ||
| CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease | Q45298950 | ||
| Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex | Q45299186 | ||
| Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice | Q45299471 | ||
| Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. | Q45299923 | ||
| Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease | Q45299926 | ||
| Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial | Q45300094 | ||
| Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. | Q45300316 | ||
| Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice | Q45300908 | ||
| Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia | Q45300939 | ||
| Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 | ||
| Cerebral metabolism and atrophy in huntington's disease determined by18FDG and computed tomographic scan | Q45304491 | ||
| Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model | Q45304699 | ||
| Modulation of nucleosome dynamics in Huntington's disease | Q45304739 | ||
| Reversal of long-term locomotor abnormalities in the kainic acid model of huntington's disease by day 18 fetal striatal implants | Q45304974 | ||
| Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease | Q45305057 | ||
| RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model | Q33936969 | ||
| Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease | Q33952130 | ||
| Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease | Q34168124 | ||
| Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy | Q34306865 | ||
| Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. | Q34343198 | ||
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline | Q34528059 | ||
| Neuroprotective agents for clinical trials in ALS: a systematic assessment | Q34568968 | ||
| Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. | Q34626231 | ||
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease | Q34763178 | ||
| Histone H3 variants and their potential role in indexing mammalian genomes: the "H3 barcode hypothesis" | Q35025031 | ||
| Apoptosis and caspases in neurodegenerative diseases | Q35097801 | ||
| Transcriptional abnormalities in Huntington disease | Q35113363 | ||
| Alternative excitotoxic hypotheses | Q35227246 | ||
| Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? | Q35254212 | ||
| Graft-induced behavioral recovery in an animal model of Huntington disease | Q35601129 | ||
| Coenzyme Q cytoprotective mechanisms | Q35718364 | ||
| Experimental therapeutics in transgenic mouse models of Huntington's disease | Q35752429 | ||
| A fundamental system of cellular energy homeostasis regulated by PGC-1alpha | Q35808821 | ||
| Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease | Q35918549 | ||
| Neuroprotection by tetracyclines | Q35941699 | ||
| Immune problems in central nervous system cell therapy. | Q36045396 | ||
| Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway | Q36117201 | ||
| The therapeutic role of creatine in Huntington's disease | Q36213329 | ||
| Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects | Q36225925 | ||
| Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers | Q36317837 | ||
| Lithium induces autophagy by inhibiting inositol monophosphatase | Q36321015 | ||
| The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting | Q36375898 | ||
| Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei | Q36395820 | ||
| Cell transplantation for Huntington's disease Should we continue? | Q36757844 | ||
| Huntington's disease: pathological mechanisms and therapeutic strategies | Q36822322 | ||
| Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury | Q36853743 | ||
| Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease | Q36959352 | ||
| Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice | Q37131550 | ||
| Inefficient degradation of truncated polyglutamine proteins by the proteasome | Q37592772 | ||
| Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility | Q38295951 | ||
| Evidence for specific cognitive deficits in preclinical Huntington's disease. | Q38452724 | ||
| Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea | Q39109797 | ||
| Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids | Q39114293 | ||
| Formation of γ-glutamyl-ε-lysine bridges between membrane proteins by a Ca2+-regulated enzyme in intact erythrocytes | Q39244222 | ||
| Chemical pathology of Huntington's disease | Q40217253 | ||
| Transport of energy in muscle: the phosphorylcreatine shuttle | Q40217946 | ||
| Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice | Q40436889 | ||
| Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease | Q40497396 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein | Q40662036 | ||
| Cysteamine-induced Increase of Cellular Glutathione-level : A New Hypothesis of the Radioprotective Mechanism | Q41525747 | ||
| Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. | Q42438521 | ||
| Riluzole in Huntington's disease (HD): an open label study with one year follow up. | Q42663375 | ||
| Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease | Q43263071 | ||
| Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease | Q43669934 | ||
| Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease | Q43830045 | ||
| Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine | Q43873037 | ||
| Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation | Q43931409 | ||
| MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment | Q43940983 | ||
| Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice | Q43977943 | ||
| Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease | Q44125037 | ||
| Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine | Q44131392 | ||
| Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. | Q44286601 | ||
| Minocycline for Huntington's disease: an open label study | Q44357409 | ||
| Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy | Q44406691 | ||
| IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study | Q44488139 | ||
| Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. | Q44504149 | ||
| Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial | Q44616594 | ||
| Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study | Q44685040 | ||
| Minocycline in Huntington's disease: a pilot study | Q44936949 | ||
| Minocycline safety and tolerability in Huntington disease | Q45013899 | ||
| Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease | Q45115023 | ||
| Creatine supplementation lowers brain glutamate levels in Huntington's disease | Q45239341 | ||
| Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors | Q45248313 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 1933-1953 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Huntington's disease: progress and potential in the field | |
| P478 | volume | 16 |
| Q34657321 | A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation |
| Q90045938 | An Optimization of AAV-82Q-Delivered Rat Model of Huntington's Disease |
| Q39932912 | BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. |
| Q38022265 | Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. |
| Q35356604 | Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease |
| Q61813371 | Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease |
| Q35052612 | Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells |
| Q46666414 | Gene expression profiles of mouse striatum in control and maneb + paraquat-induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts |
| Q35370058 | IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease |
| Q38247021 | IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity |
| Q28748849 | Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease |
| Q53346541 | Insulin/IGF-I and related signaling pathways regulate aging in nondividing cells: from yeast to the mammalian brain. |
| Q37696477 | Integrating metabolism and longevity through insulin and IGF1 signaling |
| Q38161837 | Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration |
| Q37617954 | MicroRNA implications across neurodevelopment and neuropathology |
| Q34163054 | Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease |
| Q37776087 | Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease |
| Q30481208 | Mouse models of Huntington's disease and methodological considerations for therapeutic trials |
| Q28547107 | PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease |
| Q37648786 | PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease |
| Q57675694 | Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS |
| Q33945688 | Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease |
| Q37798079 | The clinical and genetic features of Huntington disease |
| Q38975954 | Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons |
Search more.